ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective

Other authors

Institut Català de la Salut

[Koessler T] Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. [Alsina M] Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Arnold D] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. [Ben-Aharon I] Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel. [Collienne M] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. European Organisation for Research and Treatment of Cancer, Brussels, Belgium. [Lutz MP] Caritasklinikum, Saarbrucken, Germany

Vall d'Hebron Barcelona Hospital Campus

Publication date

2022-10-28T12:42:25Z

2022-10-28T12:42:25Z

2022-04



Abstract

Neuroendocrine tumours; Pancreatic cancer; Stomach cancer


Tumores neuroendocrinos; Cáncer de páncreas; Cáncer de estómago


Tumors neuroendocrins; Càncer de pàncrees; Càncer d'estómac


There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.


This work was supported by a donation from the Swiss Cancer Research Foundation from Switzerland. MC was supported by a grant by EORTC Cancer Research Fund (ECRF) and the Gastrointestinal Tract Cancer Group.

Document Type

Article


Published version

Language

English

Publisher

Elsevier

Related items

ESMO Open;7(2)

https://doi.org/10.1016/j.esmoop.2022.100392

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)